Researchers at the Centre for Genomic Regulation at the Barcelona Institute of Science and Technology have developed the Eye-in-a-Care-Box (ECaBox), a perfusion device that preserves the viability of donor eyeballs. By delivering oxygen-rich fluid through the artery that normally supplies the eye with blood, the system prevents rapid cellular degeneration, potentially enabling future whole-eye transplants.
The biological clock for a removed eye is brutal. Without a blood supply, the organ begins to degrade almost immediately. Previous attempts at whole-eye transplantation, such as a May 2023 procedure at NYU Langone involving a man who two years earlier had survived a high-voltage electrical accident, resulted in a recovery where the man wasn’t able to see out of the transplanted eye. The primary hurdle is the rapid loss of retinal function and structural integrity once the eye is excised.
How the ECaBox prevents retinal decay
The ECaBox functions as an external life-support system for the eye. It utilizes perfusion—a process of providing surgically removed organs with some of the oxygen and nutrients they typically get when they’re inside a body—to mimic the body’s natural circulatory system. The device secures the eye on a specialized bed, pumping fluid directly through the artery that normally supplies blood to the ocular tissue. A sealed environment maintains precise temperature and pressure, while a transparent window allows for real-time imaging and study.
The technical difference between perfusion and standard preservation is stark. In the team’s experiments with pig eyes—chosen for their anatomical similarity to humans—organs kept at room temperature degraded rapidly. Even cooling the eyes to 4 °C (39 °F) failed to stop the decline; the organs degenerated within 24 hours. In contrast, eyes maintained in the ECaBox remained “significantly more viable” after the same period, according to the researchers.
The device doesn’t just preserve structure; it maintains function. Untreated pig eyes lost the ability to respond to light immediately upon removal. However, the researchers found that this ability returned after approximately 15 minutes of perfusion in the ECaBox, with some eyes maintaining light responsiveness for over 10 hours.
What happened during the human eye trials?
To validate the technology, Pia Cosma and her colleagues transitioned from porcine models to human donors. The team collected 12 eyes from six people who had died. To ensure a controlled baseline, they used a split-sample methodology: one eye from each pair was placed in the ECaBox, while the other was not.
The results indicated that the perfused eyes fared better than the controls, specifically in the preservation of the retinas. While the research has been published in a preprint article and has not yet undergone formal peer review, the data suggests a path toward maintaining donor eyes long enough for complex surgical integration.
- Control Group: Rapid retinal degradation and loss of cellular structure.
- ECaBox Group: Preserved retinal viability and maintained electrical signal transmission.
- Key Metric: Restoration of light response within 15 minutes of perfusion.
Why this matters for the future of transplantation
A whole-eye transplant is an entirely different engineering challenge. If the eye is dead or degraded by the time it is sewn in, the connection is useless.
Shannon Tessier of Massachusetts General Hospital, who studies organ perfusion but was not involved in this specific research, described the development as “really cool” and noted it “could be a new frontier for retina preservation.” However, Tessier cautioned that the ultimate success of the ECaBox remains unproven until the treated eyes are actually transplanted and tested for sight.
The implications extend beyond surgery. The ECaBox provides a platform for studying eye treatments on human tissue without the need for experimenting on living animals.
What are the next steps for the ECaBox?
The current iteration of the device is a laboratory tool. To make whole-eye transplants a clinical reality, the technology must move from the lab to the operating theater. Cosma and her colleagues stated in their preprint that they plan to develop a portable, surgery-room version of the ECaBox.
The goal of a portable unit is to minimize degradation by initiating perfusion immediately in heart-beating donor eyes, when they become available. By reducing the initial degradation window, the team hopes to maximize the chances that a transplanted eye can actually transmit visual data to the brain.
For further technical context on organ preservation and the challenges of neural reconnection, resources such as the IEEE Xplore digital library and Nature provide extensive peer-reviewed data on bio-engineering and regenerative medicine. The trajectory of this research mirrors broader trends in medical technology where “ex vivo” organ support is becoming a standard for increasing the window of transplant viability.
